Geen internetverbinding — de opgeslagen versie van de pagina wordt getoond.

Mesoblast Ltd

USUSD
← Naar de screener

Mesoblast Ltd (AU:MSB) — Biotechnology: Biological Products (No Diagnostic Substances). Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 2. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.

Over het bedrijf

Website
mesoblast.com
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hoofdkantoor
MELBOURNE, VICTORIA, Australia
CEO
Silviu Itescu
Werknemers
108
Uitstaande aandelen
1.3 mld. per 2026-06-30
Free float
861.1 mln.
Marktkapitalisatie
1.48 mld. USD
Insiders
36.28%
Institutionele beleggers
17.44%
Branche (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
AU000000MSB8
FCF
−60.6 mln. USD
Schuld
127 mln. USD
netto kaspositie
Winst en FCF — voor de 12 maanden tot 31.12.2025 (het laatste rapport van het bedrijf).
Beschrijving

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Beurzen en tickers

BeursTickerValutaPrijsType
US USA StocksMEOBF OTCUSD1.53 +10.07%gewone aandelen
AU Australian Securities ExchangeMSB primairAUD2 +3.36%gewone aandelen

Koers over 3 maanden

stijgingsdag dalingsdagBeweeg over / tik op een dag — openings-, slot-, hoogste en laagste koers

Nieuws deze week

Nog geen nieuws van de website van het bedrijf.

advertentie

Grootste aandeelhouders

HouderBelangAandelenRapportdatum
Itescu (Silviu) (Chief E…≈6.23%80.84 mln.2026-07-17
VANGUARD STAR FUNDS-Vang…1.05%13.66 mln.2026-04-30
VANGUARD TAX-MANAGED FUN…0.62%8.01 mln.2026-06-30
iShares Trust-iShares Co…0.53%6.88 mln.2026-07-31
Rose (Eric) (Director (N…≈0.52%6.75 mln.2026-01-09
DFA INVESTMENT TRUST CO-…0.36%4.68 mln.2026-04-30
VANGUARD Intl Eqy. INDEX…0.27%3.51 mln.2026-04-30
iShares Trust-iShares MS…0.24%3.07 mln.2026-07-31
SCHWAB STRATEGIC TRUST-S…0.15%1.99 mln.2026-05-31
Dimensional ETF Trust-Di…0.11%1.38 mln.2026-04-30
iShares Trust-iShares Co…0.09%1.23 mln.2026-07-31
SPDR INDEX SHARES Fd.S-S…0.09%1.19 mln.2026-08-31
Bell (Jane Catherine) (D…≈0.05%622 4922025-02-28
Burns (William) (Indepen…≈0.02%226 2502025-10-21
Legato Capital Managemen…0.01%47 3802022-06-30
Cobley (Lyn Elizabeth) (…≈0%63 0002026-01-09